Who’s ready for the @SpaceX IPO?
SpaceX is aiming to file its IPO prospectus as soon as early next week, per multiple reports. Listing possible in June.
• Potential Raise: Over $75 billion — could be the largest IPO in history!
• Target Valuation: ~$1.5–1.75 trillion.
$ALGS back on the move 6M share float /$80M MC, anchored by best-/first-in-class CHB backbone therapy advancing through mid-Phase 2b, alongside a high-value MASH program with recent GLP-1 + ALG combination data demonstrating weight loss, potential out-licensing deal in 1H ’26.
One year ago $TERN was $5.50. It just hit $45.00 (+720%). That’s biotech — the gems are out there if you’re early and patient.
I officially added $TERN to my bio portfolio. I believe they are highly undervalued with multiple drugs in thier pipeline. TERN-601 (GLP-1), TERN-501 (THR-β agonist) and TERN-701 (treating CML) with an expected update im early December.
7
2,098
IPO ARMY retweeted
$ALGS one to watch again.
This time last year ran from $7 to $46, in a month and a half. After that it was insanely oversold to ~$4 a share, now at $9.
Another example of an undervalued biotech, amazing opportunity.
Up 35.5% this week, smart money is starting to roll back in.
$3B valuation for MASH P3. What’s the combined valuation for $ALGS with best/first-in-class MASH + CHB? CEO says MASH deal expected early 2026. Who makes the next move — @merck @pfizer @JNJNews @GileadSciences ?
$ETNB stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash represents total equity value of up to approximately $3.5B.
1
1,376
$ETNB stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash represents total equity value of up to approximately $3.5B.
They expect to announce out licensing deal for mash drug before year end.
$ALGS worth watching yesterday’s conference!
investor.aligos.com/events/e…
1
1
1,122
$ALGS worth watching yesterday’s conference!
investor.aligos.com/events/e…
It’s also the only publicly traded player this close to potentially changing the standard of care. With a regulatory decision possible as early as 2026, the timeline is closer than most realize.
3/4
1
1
764








